Under construction – not a live service
Sign in
Taking people in ItalyPhase 4

Long-term safety of pirtobrutinib in people with leukemia or lymphoma

Checks long-term safety of pirtobrutinib in adults with CLL or lymphoma who finished earlier studies.

Plain-language title generated from the registry record
Registry title: A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Key facts

Where
Bologna and Milan, ItalySee the 2 sites
Phase
Phase 4

Where in Italy

  • IRCCS-AOU di Bologna-Policlinico S.Orsola-MalpighiBologna, ItalyTaking people
  • Ospedale San RaffaeleMilan, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Eli Lilly and Company
Trial code
NCT06876649
Record updated
2 March 2026
Original description
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.Read full original descriptionShow less

A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.

Inclusion: Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.

ClinicalTrials.gov NCT06876649